The Effect of Capecitabine and Cisplatin as a Radiosensitizer in Radiation of Bladder Cancer
Phase 1
- Conditions
- Bladder cancer.Malignant neoplasm of bladder, unspecified
- Registration Number
- IRCT20180815040801N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Patients with muscle invasive bladder cancer (T2 to T4a)
TCC pathology
Patient's refusal of radical cystectomy or not being candidate to do that due to medical comorbidities
Referred by an urologist for concurrent chemoradiation of bladder cancer
Exclusion Criteria
Hydronephrosis that does not resolve with usual treatments
Lymphatic or distant metastasis
Cr>2
GFR <30
WBC<3000
PLT<80,000
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The amount of treatment tolerability and completion in adding capecitabine to cisplatin in comoradiation of muscle invasive bladder cancer. Timepoint: Weekly during treatment and three months after termination of the treatment. Method of measurement: CTCAE 4.03 2010 (Common Terminology Criteria for Adverse Events).
- Secondary Outcome Measures
Name Time Method